BUZZ-Street View: New growth drivers show promise to boost Medtronic's revenue

Medtronic on Tuesday missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by distributors, and said the problems would persist in the current quarter

PLETHORA OF CATALYSTS AT PLAY

J.P. Morgan ("Neutral", PT: $95) says there are reasons to stay more positive into FY26 with growth in co's diabetes and heart device business, along with contribution from new products which are used for procedures such as renal denervation and pulsed field ablation

RBC Capital markets ("Outperform", PT: $105) says MDT has "plethora of catalysts at play" including its surgical robot Hugo and expansion in its portfolio for cardiac devices, along with significant opportunity in renal denervation

UBS ("Neutral", PT: $95) sees potential for continued improvement in diabetes segment

Citi ("Neutral", PT: $92) says Medtronic is standing on the threshold of several new growth drivers that are starting to gain traction